Analytical and clinical comparison of three PD-L1 antibody clones using Tumor Area Positivity (TAP) and Combined Positive Score (CPS) scoring in advanced gastric cancer
- 27 October 2026
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- p. 1-12
Abstract
No abstract availableKeywords
Funding Information
- Korean Gastric Cancer Association (KGCA-24-03-B)
This publication has 20 references indexed in Scilit:
- Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repairGastric Cancer, 2024
- Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapyGastric Cancer, 2024
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2023
- Impact of Decalcification, Cold Ischemia, and Deglycosylation on Performance of Programmed Cell Death Ligand-1 Antibodies With Different Binding Epitopes: Comparison of 7 ClonesLaboratory Investigation, 2023
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal AdenocarcinomaLaboratory Investigation, 2023
- Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapyGastric Cancer, 2022
- Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimensPathology, 2021
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapiesLaboratory Investigation, 2020